1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Chronic Hepatitis C in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Caini, P; Giannelli, F; Giannini, C; Gragnani, L; Guerra, CT; Laffi, G; Monti, M; Petrarca, A; Solazzo, V; Zignego, AL | 2 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Chronic Hepatitis C
Article | Year |
---|---|
Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antiviral Agents; Apolipoprotein B-100; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrophages; Male; Middle Aged; Platelet Activating Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Viremia | 2007 |
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Apolipoprotein B-100; Carrier State; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrophages; Male; Middle Aged; Platelet Activating Factor; RNA, Viral; Vasculitis | 2007 |